Eli Lilly reported results and guidance that outstripped Wall Street expectations as its GLP-1 obesity franchise continued to drive revenue. The company said combined 2025 sales for Zepbound and Mounjaro exceeded $36 billion and delivered guidance that calmed investor concerns about pricing pressure. Analysts contrasted Lilly’s outlook with weaker signals from some peers, underscoring the company’s dominant commercial position in the obesity market. The report highlighted durable demand despite debates over pricing and reimbursement. Management framed the results as validation of Lilly’s launch execution and market share gains across weight-loss and diabetes indications. Investors and competitors will watch how pricing, payer reactions and new entrants shape growth into 2026.